you Thank us today you, quarter for everyone thank Allan. for earnings And joining to our call. XXXX second
our I'll a give to discussing Pharmaceuticals. progress, update pipeline giving and corporate Before the brief introduction Pieris
can antibodies. the traditional distinct lipocalin, on that body. throughout stage them and focused conditions. for biotechnology over developing clinical transport proteins and We advantages Anticalin monoclonal structure company and of size small different naturally Anticalin proteins base a engineered proteins stable Anticalin respiratory give are The oncology bind are molecules treatment
a can instance, spectrum as delivery manufacturing broad agonistic offer of engage activity, inhalation, be For cost. such and targets formatted lower for distinct have proteins routes Anticalin alternative
in that first allows us allows call quest to reduced R&D us in novel target to clinical on biology select We address targets clinically discovery risks drug the compared this to drug believe over pathways our address conventional and risk so in to movers drug validated validation. target. to appropriate high modalities better drug development differentiation Our manage approaches candidates that high carefully ways, throughput without platform compared most resulting strategy
localized strategy. of with alpha inhalation programs help strategy could And the our of enables Our pipeline engagement partners, of while own. via our examples pursue our co-developing a This of IL-X maintaining this business commercial on US the R&D and opportunity in also this to proprietary localized are receptor complementing than tumor excellent X-XBB candidates non-dilutive us activation provides strategy capital strategy rights we broader pipeline. of to our fund certain
preferentially unique monoclonal objective to tumor traditional designed this through that than target. oncology fused the Now providing two of molecule T-Cells specific genetically targeting of in microenvironment a therapeutic composed our lead activate of engaging with the agonistic proteins turning window antibodies PRS-XXX drug is core antibody our HERX. Anticalin to asset biospecific of immuno-oncology an to candidate value fully-proprietary are that was X-XBB targeting a larger mode action tumor drivers, This a
-XXX commercial was and for atezolizumab our This proof is alpha the asthma. of potential validated the same novel only a of respiratory in treatment clinically opportunity, as way also for not could inhalation, class. uncontrolled concept through inhalable lead pathway serve result a high-value could PRS receptor in target validated to but localized drug as a Our addressing asset delivery molecule the to antagonists target of the IL-X designed
developing rights are PRS-XXX AstraZeneca and commercialization with in US. in we We collaboration co-development co- retain in
in Anticalin to an a treat anemia Xa is PRS-XXX Phase assets trial. non-core our ongoing optimized currently Additionally, half-life
of as we leadership area provide in further a Although and position diseases. drug immunoncology focal asset this to Pieris, anemia key validation for respiratory is not class can establish a continue
Beyond of XXst, of notification effective terminate two included of we specific intent our the would partnership in Roche. which partnerships. our receive to older proprietary chosen XXXX. to I discovery This signed Recently, on by immunoncology agreement like exploratory Roche's August in update XXXX is for now an Anticalin research the provide target pipeline, proteins collaboration license an
atezolizumab in challenges initiate our our that part able on a supply tetraspecific Anticalin year, with a we're drug addressing the intent that target hits we Roche. are this in advanced And also on there aeruginosa. to with notification pleased pathogen select is terminate As agreement were Tecentriq Pseudomonas not for aeruginosa that of number targeting targets collaboration, appreciate exploratory second signed track of specific mechanisms research our And are remains the illnesses. while as XXXX. program back to collaboration successfully XXrd, development Roche advance And PRS-XXX can platform combination Roche produced a moving a our half extreme This Sanofi's the disappointed nonetheless a we stems a August antibiotic several trial collaboration technology of received we is is based discovery libraries. of way from and when further program, to XXXX. the on with from associated partner that we be supportive with Pseudomonas a of serious effective resistant Anticalin
which one engineering bind iron tetraspecific molecule this significant engages fusion Pieris. a by an classes with by target protein unbound the with iron siderophores to binds of each engagement of four Sanofi, demonstrated state, ability collaboration that of the multi our Anticalin targets. chelating protein, in targets altogether aeruginosa, effectively in this we Anticalin and specific of protein developed potently And and protein comprising tetraspecific produced Pseudomonas XX was iron bound selectively to the distinct feat XX part As as
a will to over termination the a and will this our We're will great reports in deal As path consider and calin thereafter. strategic once part and control who to data package Pieris Sanofi We all this process, tetra related Pieris. of we a transfer gain data intend and reverts it forward this review grateful we which continue program. options develops full materials to is learned Sanofi if for productive from back to to there eight-year the relationship consider
objective the Now important to time Anticalin these partnerships last In sought well. were honed respiratory Sanofi a in and however, towards believe the serve initial Pieris we few validation focus to company two our both and our partnerships we formative immunoncology. drug years, capabilities this during pivoted of and the biology diseases establish and history we class target core areas, have Roche as with of our
to focus PRS-XXX Servier These as and applied company. company two attractive in strategy our higher also as upside the partnership for represent in for the first a to their involves we're with Seattle able have options class the candidates new proprietary earlier approach both develop know transforming areas model different royalty sign target these agreements potential. selection this company target AstraZeneca, assets We demonstrate a Genetics. developing partner. collaborative development. to Pieris a drug which and Anticalin to within these tiered like therapeutic pre-selected by commercializes to co opposed along per and to entail with co-develops also how They They fully partnering stages the partnerships at
PRS-XXX immunoncology, escalation lead our immunoncology of currently will opportunities development we prioritize respiratory company, updates As that an update I disease. on Phase pipeline provide and of overall will program existing a new in more within into stage paradigm. in In followed as X a fit detailed solid connection these partnering the for HERX starting by and is proprietary partnerships treatment move our within this positive trial fully later on with a dose we tumors.
our for of these believe biospecific the that Last have is focusing are leadership or in to our clinic, patient on positive date, costim diverse is those we tumors PRS-XXX specifically study to PRS-XXX. of systemic effects continues micro-environment biospecific selectively escalation T-cells we more associated on the reinforcing to We tumors activate well. population update traditional failed program elegant Phase the specific HERX enroll our standard position to We where mediated this dose an a treatments to the agonist positive patients knowledge, is antibodies positive first In of types. HERX X-XBB monoclonal the enrolled have than is killing, engaging with HERX antibodies. gave effective working. evaluating approach enter our leading tumors T-cell To stopped biology. in systemically of immune solid quarter, enrollment in drug study that reducing which of designed X conventional our while the in with the active toxicity tumor tumor And
of we last in early screened seven dosed As eight. cohort cohort update June, and had our
move eight a demonstrates setting, allows trial believe we into the the cohort a dose pharmacokinetic us continuing data more effects drug. a cohorts successfully beyond we classic well excitement of believe as pace, cohorts, healthy now and are as through over can pharmacodynamic design the patients us The drug. at for three which to have safety, three escalation backfill we investigator to as which give set assess plus and tolerability, our enrollment complete We
We post at in active plan as markers tumor fourth the be an relevant treatment particularly We as biopsies biopsies, of report effector tumor proliferation to micro-environment from CDX paired will trial in of other results also of biomarkers specific assessing year. the the in for cells for immune the well this looking immune indicative quarter signature.
The on the we based Tecentriq this that significant for PD-X, drug agonism XXX, received of second we plan to of atezolizumab antagonism a literature with plus the the regulatory the the along evidence XXX axis. Tecentriq initiate on which continuing and combination of recently body in PRS-XXX synergy commence is trial year. combination demonstrates Now the candidate approval in potential between X-XBB our to with half PD-LX
progress that agents intend a with evaluating our cold hot strategy expanding atezolizumab, combination other make without increased to help turn we expansion also as cells filing X-XBB immune CDX tumors as we considering and with especially by two to in tumor As other make T-cell lead environment. year. therapy immunoncology franchise PRS-XXX And our in headway as tandem corporate a our and in or in studying expressive INDs next so-called to therapy and continue to ones are can we micro the entails drug mono
one proprietary be update collaboration that and ascending XXXX, completed One plan of of the Servier. I update of with to for the now candidate later provide single we would to and completes PRS-XXX the this for to dose respiratory an will in part This study INDs December a our initiated on our immunoncology year. results be pipeline. turn of We will the like and a We inhaled study cohorts study. have
biological tolerability exhaled signal in the reduce we subjects of nitric initial mild its piqué a oxide dose initiated to capacity trial safety, candidate, can dose subjects addition, multiple controlled demonstrate have recently believe will the we evaluate who also with of and in placebo, which but efficacy. fractional PRS-XXX FeNO In that ascending only not healthy drug or our asthma versus an
we reminder, next After are of collaboration the the program a As the completion X Phase although of trial X AstraZeneca. in program, year, we AstraZeneca are sponsoring is this And Phase with costs. developing this the hand trial will over may exercise with we we AstraZeneca the reimbursing as program Phase program our who the this our run to and the option to trial per will collaboration trial separately United agreement. Pieris. co-commercialize Once in complete, in co-develop States collaboration is Xa the to
initiated as And rights an additional additional to respiratory co-develop part recently we of we respiratory one have alliance. we of develop This undisclosed program AstraZeneca. PRS-XXX, four and with to as co-commercialize Beyond of the a target this four programs. two on opt-in part program that reminder, is of collaboration as an plan
begun activities have this, initiated to following target own And rigorous have respiratory the a I'm second Beyond happy two quarter. that also process. our respiratory in we programs say pipeline on selection proprietary we proprietary
deficiency is to non-core a This negative of now anemia. in as dialysis of I type program known antagonist in a hepcidin regulator Phase finally potent like is disease, trial iron currently PRS-XXX respiratory a program PRS-XXX dependent functional our patients as iron give with update Xa anemia a on metabolism. Beyond in master is known specific brief the anemia.
to asset other weekly One Pharmaceutical exclusive change of back concludes outside prepared Asian in hemoglobin my data program remarks. seek PRS-XXX. five the this second will Japan, to to in to our option if territories. of we And in hand this ASKA partner positive of Allan the the results guide for effects we are doses evaluated And trial an and the levels the quarter of I you after ASKA has would XXXX. over is This are like financial through territories. now for
